BCAL Diagnostics Limited

Equities

BDX

AU0000160921

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 01:03:59 2024-06-05 EDT			5-day change	1st Jan Change
0.14 ^AUD	+12.00%		-20.00%	+41.41%

06-03	BCAL Diagnostics Shares Resume Trading After Equity Raising Announcement	MT
06-03	BCAL Diagnostics Receives Firm Commitments for AU$10.5 Million Placement at AU$0.10 Per Share	MT

BCAL Diagnostics Limited in Collaboration with GenesisCare Clinical CRO, Expanding Clinical Study Centres to Al States of Australia

August 16, 2021 at 08:26 pm

BCAL Diagnostics Limited, in collaboration with GenesisCare Clinical CRO, is expanding clinical study centres to al states of Australia. Additional agreements are under review and will enable BCAL to maintain the pace of development, notwithstanding the closure of a number of breast cancer screening centres due to COVID-19.

Latest news about BCAL Diagnostics Limited

BCAL Diagnostics Shares Resume Trading After Equity Raising Announcement	06-03	MT
BCAL Diagnostics Receives Firm Commitments for AU$10.5 Million Placement at AU$0.10 Per Share	06-02	MT
BCAL Diagnostics Appoints CEO	03-05	MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-20	CI
BCAL Diagnostics Joins Forces to Conduct Breast Cancer Blood Test Study in India	11-29	MT
BCAL Diagnostics Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Fall 5%	11-13	MT
BCAL Diagnostics Files for Additional Australian Patent Application	11-06	MT
BCAL Diagnostics Appoints COO	23-09-04	MT
Bcal Diagnostics Limited Appoints Shane Ryan as Chief Operating Officer Effective 21 September 2023	23-09-04	CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
9,246,318 Ordinary Options of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	23-07-20	CI
54,752,379 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	23-07-20	CI
BCAL Diagnostics Appoints Advisor	23-05-15	MT
Bcal Diagnostics Limited Opens New Laboratory in Sydney	23-05-04	CI
BCAL Diagnostics Opens Laboratory in Sydney	23-05-03	MT
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
BCAL Diagnostics to Set Up Clinical Service Laboratory in Sydney	22-10-26	MT
BCAL Diagnostics Limited Announces Establishment of Development & Clinical Service Laboratory	22-10-24	CI
BCAL Diagnostics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
BCAL Diagnostics Limited Enters US Product Development Agreement with Precion Inc	22-06-27	CI
20,596,692 Ordinary Shares of BCAL Diagnostics Limited are subject to a Lock-Up Agreement Ending on 20-FEB-2022.	22-02-19	CI
BCAL Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-17	CI
Bcal Diagnostics Limited Provides Additional Information on Recent Analysis to Distinguish Between Blood Samples of Breast Cancer Patients and Normal Control Samples	22-02-07	CI
Bcal Diagnostics Limited Announces Recent Analysis Significantly Improves Commercial Prospects	22-02-06	CI
BCAL Diagnostics Names New CEO	22-01-10	MT

Chart BCAL Diagnostics Limited

Duration

Period

More charts

Company Profile

BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Companyâs principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BCAL DIAGNOSTICS LIMITED	+41.41%	20.96M
BIOMÉRIEUX	-4.67%	12.35B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.76%	8.17B
DIASORIN S.P.A.	+8.05%	5.77B
LANTHEUS HOLDINGS, INC.	+31.48%	5.65B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.28%	4.1B
ANDON HEALTH CO., LTD.	+10.72%	2.67B
10X GENOMICS, INC.	-61.53%	2.57B
VITROLIFE AB	-7.81%	2.31B
MYRIAD GENETICS, INC.	+16.56%	2.02B

Diagnostic & Testing Substances